Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
Q1FY27 Revenue down 42% YoY; Management moderates FY27 growth guidance
Shree Ganesh Remedies reported a weak Q1FY27 with revenue falling 42% YoY to ₹14.36 Cr and PAT declining 68% YoY to ₹1.12 Cr. The downturn was primarily caused by subdued European demand and the termination of a marketing agreement with an EU distributor due to non-performance. Consequently, management has moderated its earlier guidance of 'non-linear growth' for FY27, now expecting a recovery only in the second half of the year. Despite the short-term setback, the company is continuing its Ankleshwar site expansion and Dahej land acquisition for future capacity.
high confidence
What changedSignificant quarterly performance decline and a formal moderation of the FY27 growth outlook from 'non-linear' to recovery-based.
Why it mattersThe company is transitioning from a distributor-led model to direct customer engagement in the EU, which creates a short-term volume gap but aims for higher long-term control and margins.
Q1FY27 Revenue: ₹14.36 CrYoY Revenue Change: -42%Q1FY27 PAT: ₹1.12 CrYoY PAT Change: -68%EBITDA Margin: 23.3%Debt to Equity (FY26): 0.18
📅 Short termNegative sentiment is expected due to the sharp earnings miss and the guidance downgrade, with recovery unlikely before H2FY27.
📈 Long termThe structural shift towards niche specialty chemicals and direct EU sales remains the focus, but long-term value depends on the successful execution of the Ankleshwar and Dahej expansions.
⚠ Risk flags
Geopolitical uncertainty affecting EU demand
Distributor transition risks
Volatility in raw material markets
👀 What to Watch
Monitor the restoration of volumes in the EU market following the distributor termination and the commissioning timeline of 'Block 7' at the Ankleshwar site. Watch for the start of revenue contributions from South-East Asian CRAMS projects in H2FY27 as a recovery signal.
68% PAT drop in Q1FY27; SGRL moderates FY27 growth guidance amid European headwinds
Shree Ganesh Remedies Ltd (SGRL) reported a weak Q1FY27 with revenue declining 42% YoY to ₹14.36 Cr and PAT falling 68% YoY to ₹1.12 Cr. The performance was severely impacted by subdued demand in Europe and the termination of a non-performing distributor agreement, leading management to withdraw its earlier guidance of 'non-linear growth' for FY27. EBITDA margins contracted significantly to 23.3% from 29.6% YoY, reflecting lower operating leverage and raw material volatility. The company expects a recovery in H2FY27 driven by new CRAMS projects and direct customer engagement in Europe.
high confidence
What changedSGRL has shifted from a distributor-led model to direct sales in Europe following a contract termination and has officially lowered its growth expectations for FY27.
Why it mattersThe sharp earnings miss and guidance downgrade are significant for a company trading at a high P/E of 44.9, as it indicates a temporary break in the growth trajectory and margin profile.
📅 Short termThe stock is likely to face downward pressure in the short term due to the substantial earnings miss and the withdrawal of aggressive growth guidance.
📈 Long termThe long-term outlook depends on the company's ability to restore volumes through direct sales and the successful execution of its specialty chemicals expansion at the Ankleshwar site.
⚠ Risk flags
Geopolitical uncertainty affecting European demand
Execution risk in transitioning to direct sales
Margin pressure from raw material volatility
Guidance downgrade
👀 What to Watch
Investors should monitor the timeline for the commissioning of Block 7 and the progress of direct customer acquisition in Europe to replace the terminated distributor. The key recovery trigger will be the commercialization of CRAMS projects in South-East Asia, expected in H2FY27.
Shree Ganesh Remedies (SGRL) reported a weak set of numbers for Q1 FY27, with standalone revenue falling 41.8% YoY to Rs 14.36 Cr. Net profit saw a sharper decline of 66.7% YoY to Rs 1.15 Cr, down from Rs 3.45 Cr in the year-ago period. The results reflect the company's previously stated 'year of consolidation' amid softer demand in Europe and contract repricing in its CRAMS business. The US subsidiary remains non-material with zero revenue for the quarter.
high confidence
What changedThe company has transitioned into a significant earnings contraction phase, with Q1 revenue representing only ~13% of the previous TTM revenue, down from a typical ~25% run rate.
Why it mattersThe sharp decline in profitability confirms the impact of external headwinds like European market softness and competitive pricing pressures on the company's high-margin CRAMS model.
📅 Short termThe stock is likely to face downward pressure in the short term as the market reacts to the significant miss in both revenue and profitability.
📈 Long termStructural recovery depends on the commercialization of specialty chemical projects for Japanese clients and the completion of the Ankleshwar expansion by mid-2026.
⚠ Risk flags
Sharp revenue contraction
Contract repricing pressure
Soft demand in European markets
High inventory volatility
👀 What to Watch
Investors should monitor the stabilization of contract repricing and the execution timeline of the Ankleshwar site expansion, which is critical for growth post-FY26.
Shree Ganesh Remedies reported a weak set of numbers for Q1 FY27, with revenue from operations falling 41.8% YoY to Rs 14.36 crore. Net profit plummeted 67.2% YoY to Rs 1.13 crore, down from Rs 3.45 crore in the same period last year. Sequentially, the performance was even more subdued, with revenue dropping 56.7% from Rs 33.20 crore in Q4 FY26. This sharp contraction aligns with management's earlier guidance of FY26 being a 'year of consolidation' amid softer European demand and contract repricing.
high confidence
What changedThe company has reported a significant year-on-year and sequential contraction in both its top-line and bottom-line for the first quarter of FY27.
Why it mattersThe results confirm the immediate impact of softer demand in Europe and downward contract repricing, which are currently outweighing the company's technical expertise in complex chemistry.
📅 Short termThe stock is likely to face negative sentiment in the short term due to the sharp decline in quarterly profitability and revenue.
📈 Long termLong-term recovery depends on the successful shift toward niche specialty chemicals and the commercialization of new capacity at the Ankleshwar site.
⚠ Risk flags
Significant revenue contraction
Sharp decline in net profit margins
Exposure to softer demand in European markets
👀 What to Watch
Investors should monitor the stabilization of CRAMS contract pricing and the progress of the Ankleshwar site expansion, which is key to post-FY26 growth. Watch for updates on the specialty chemicals project for the Japanese client expected by mid-2026.
📊 Last 7 days — analysed filings by sentiment
positivenegativeneutralwatch
⚠️How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI
⚡ Free FlashFinance Newsletters
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
✅ Everything below is 100% free — no payment, no card, ever.
🎉
You're subscribed!
A welcome email with your topics is on its way. Want it even faster? Join us on Telegram or WhatsApp:
